in liver pathology? 2014 What s hot

Similar documents
Liver Pathology in the 0bese

New insights into fatty liver disease. Rob Goldin Centre for Pathology, Imperial College

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Liver biopsy as the gold standard for diagnosis. Pierre BEDOSSA

PHC, Paris, 30th Jan 2017 PATHOLOGY OF NAFLD. Pierre Bedossa. Departement of Pathology Hôpital Beaujon University Paris-Diderot Paris - FRANCE

DIAGNOSIS OF NASH LIVER BIOPSY. PHC

Steatotic liver disease

European. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes

Liver Specialty Evening Conference. Matthew M. Yeh, MD, PhD Professor of Pathology Adjunct Professor of Medicine University of Washington, Seattle

Pitfalls in the diagnosis of well-differentiated hepatocellular lesions

Non-Alcoholic Fatty Liver Disease An Update

Enterprise Interest Nothing to declare

Challenges in the Diagnosis of Steatohepatitis

AASLD: Boston Rob Goldin

PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy

LIVER PATHOLOGY. Thursday 28 th November 2013

Pathological Analysis of Small Hepatocellular Carcinoma with Poor Prognosis

Liver Cancer. Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine

Role of Liver Biopsy. Role of Liver Biopsy 9/3/2009. Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging

Linda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology

Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?

Intrahepatic cholangiocarcinoma Histologic spectrum, novel markers and molecular assays

Cirrhosis is different from Fibrosis

Autoimmune Liver Diseases

FDA Introductory Remarks Stephanie O. Omokaro, MD

DILI PATHOLOGY. PHILIP KAYE November 2017 BSG Pathology Winter Meeting

UC SF. Liver and Gastrointestinal Pathology Update. University of California San Francisco. September 3, 2009

Automatic Pathology Software for Diagnosis of Non-Alcoholic Fatty Liver Disease

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

PATHOLOGY OF LIVER TUMORS

British Liver Transplant Group Pathology meeting September Leeds cases

Pathology of Fatty Liver Disease

FATTY LIVER DISEASE (NAFLD) (NASH) A GROWING

Original Article. Significance of Hepatic Steatosis in Chronic Hepatitis B Infection INTRODUCTION

PREVALENCE OF NAFLD & NASH

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

Cholangiocarcinoma. Judy Wyatt Dundee November 2010

Liver Pathology Symposium - medical livers

O Farrell Legacy UPDATE ON WHO NOMENCLATURE. World Health Organization, 2010 DISCLOSURES WITH EMPHASIS ON PROBLEM HEPATOCELLULAR TUMORS

Transient elastography in chronic liver diseases of other etiologies

Transient elastography in chronic viral liver diseases

HEPATOCELLULAR CARCINOMA: AN OVERVIEW

Advances in Understanding Hepatic Fibrosis and Chronic Liver Disease

Clinical Trials & Endpoints in NASH Cirrhosis

Improving Access to Quality Medical Care Webinar Series

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology

Updates from the AASLD

PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017

Histological subclassification of cirrhosis based on histological haemodynamic correlation

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012

Viral Hepatitis (I) Luigi Terracciano Department of Pathology University Hospital Basel. Basel,

Evaluation of Liver Mass Lesions. American College of Gastroenterology 2013 Regional Postgraduate Course

Case #1. Digital Slides 11/6/ year old woman presented with abnormal liver function tests. Liver Biopsy to r/o autoimmune hepatitis

Liver Transplant Pathology a general view

Screening for Portal Hypertension in Cirrhosis

Fibrosis stage reference images

21/07/2017. Update on Autoimmune Biliary Disease. Changing Role of Liver Biopsy in PBC and PSC. Primary Biliary Cirrhosis Cholangitis

Making the best use of liver biopsy: clinical perspective. Steve Ryder Wolfson Digestive Diseases Centre University of Nottingham

Alastair Burt Newcastle University

LIVER PATHOLOGY. Thursday 28 th November 2013

Outline. Hepatocellular Carcinoma Histologic variants. HCC: Histologic variants

Hepatitis C wi w t i h Ju J dy y W y W a y t a t t

21/02/2014. Disclosures. HCC: predicting recurrence. Outline. Liver transplant: Beyond Milan?

First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health

Dhanpat Jain Yale University School of Medicine, New Haven, CT

Hepatocellular Carcinoma. Markus Heim Basel

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants

EVALUATION OF ABNORMAL LIVER TESTS

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI

Atypical Well differentiated Hepatocellular Neoplasms Cruising through the maze of criteria, terminology and risk assessment

Hepatocellular carcinoma

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease

Risk stratification in PBC

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Chronic Biliary Disease. Dr Susan Davies & Dr Bill Griffiths

Autoimmune Hepatitis: Histopathology

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014

Overview of PSC Making the Diagnosis

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic

Interface hepatitis in PBC: Prognostic marker and therapeutic target

Do Histological Features Inform DILI mechanisms?

NON INVASIVE EVALUATION OF DISEASE PROGRESSION IN CHRONIC LIVER DISEASES

Nottingham Patterns of liver fibrosis and their clinical significance

Evangelos Chartampilas Bioclinic Hospital Thessaloniki, Greece

BSG/ACP annual course Royal College of Pathologists Infections and Inflammations of the Hepato-Biliary System Hepatitis B and D

Jesse Civan, M.D. Medical Director, Jefferson Liver Tumor Center

Nash with cirrhosis icd 10

M30 Apoptosense ELISA. A biomarker assay for detection and screening of NASH

NASH : Diagnosis and investigation. VII Workshop international, Curitiba, Brazil 29/08/2014

Slide 7 demonstrates acute pericholangitisis with neutrophils around proliferating bile ducts.

NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES

Pathology of Non-Alcoholic Fatty Liver Disease

Steatosi epatica ed HCV

Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis

When is immunohistochemistry useful in adult medical liver disease? Chris Bellamy Edinburgh

Pathogenesis of Cholangiolocellular Carcinoma: Possibility of an Interlobular Duct Origin

Preliminary clinical experience with Shear Wave Dispersion Imaging for liver viscosity

Transcription:

Medizinische Fakultät Institut für Pathologie BSG Annual Liver Pathology Update Meeting Stratford upon Avon 20 November 2014 2014 What s hot in liver pathology? Dina G. Tiniakos Dept of Cellular Pathology, Royal Victoria Infirmary Institute of Cellular Medicine, Newcastle University Newcastle upon Tyne

Medizinische Fakultät Institut für Pathologie 2014 What s hot Chronic liver disease Fibrosis Cirrhosis DILI Fatty liver disease Biliary disease Benign tumours Malignant tumours

Evaluation of fibrosis - cirrhosis

Garcia-Tsao, Hepatology 2010

All cirrhoses are not the same! Masson trichrome Sempoux & Rahier, Clin Res Hepatol Gastroenterol 2012

Laennec staging system for evaluation of hepatic fibrosis Stage 4A Beyond stage 4 Wanless, Blood 2002 Correlates with HVPG levels and clinical stages of cirrhosis Stage 4B Nagula, J Hepatol 2006 Kim, J Hepatol 2011 Stage 4C

Stage 4A Stage 4B Stage 4C

Liver Int 2014; 34:1008-17 n=92 High histological tumour grade (3-4) correlated with early recurrence and Laennec stage 4c was the only independent risk factor for late recurrence in HBV-related HCC

Evaluation of fibrosis - cirrhosis Digital quantification of collagen objective accurate assessment of fibrosis as a continuous variable Rastogi, Histopathology 2013 Collagen proportionate area (CPA) better reflects HVPG compared to Ishak score predicts prognosis of patients transplanted for CHC correlates with noninvasive fibrosis markers Calvaruso, J Gastroenterol Hepatol 2012 Huang, Liver Int 2013

n=69 J Hepatol 2014;60: 948-54 CPA was the only independent predictor of clinical decompensation in patients with cirrhosis

n=162 CHB core liver bx J Hepatol 2014;61:260-9 qfibrosis correlates well with Metavir/Ishak fibrosis stages, differentiates between Ishak stages 5 and 6 and is superior to CPA.

Extent of sinusoidal capillarisation correlates with - fibrosis stage and HAI - splachnic haemodynamic parameters Angiogenesis is an early event in CLD Tissue angiogenesis should be included in the histological assessment of CLD N=40 CHC

Medizinische Fakultät Institut für Pathologie 2014 What s hot Chronic liver disease Fibrosis Cirrhosis DILI Fatty liver disease Biliary disease Benign tumours Malignant tumours

n=249 Hepatology2014; 59:661-70

DILI: Relationship between pathological and biochemical injury patterns n=249 Kleiner, Hepatology 2014

http://livertox.nih.gov/ Free database of drugs linked to liver injury launched in 2012 Up-to-date and accurate information and case registry of DILI >1000 medications, herbals and dietary supplements.

Medizinische Fakultät Institut für Pathologie 2014 What s hot Chronic liver disease Fibrosis Cirrhosis DILI Fatty liver disease Biliary disease Benign tumours Malignant tumours

Differentiation between acute and chronic steatosis Lipid-droplet associated proteins of the perilipin/pat-family - perilipin, adipophilin, TIP47, MLDP are differentially expressed in hepatic steatosis Perilipin is expressed de novo Straub, Hepatol 2008 Straub, Mod Pathol 2010 Lipid-droplet maturation studied in vitro (cultured hepatocytes) 120 liver biopsies with steatosis of different aetiology Pawella, J Hepatol 2014; 60:633-42

Lipid droplet maturation Perilipin might be used for the differential diagnosis of chronic vs. acute steatosis Pawella, J Hepatol 2014; 60:633-42

Scoring activity in Nonalcoholic Fatty Liver Disease (NAFLD) NAS ΝASH Activity Score - Steatosis (S: 0-3) 0: <5%, 1: 5-33%, 2: 33-66%, 3: >66% - Lobular Inflammation (LI: 0-3) 0: 0, 1: 1-2, 2: 2-4, 3: >4 foci/x20 - Ballooning (B: 0-2) 0: none, 1: mild, few 2: moderate-marked, many NAS = S + LI + B, range 0-8 NAS 1-2: no NASH 3-4: borderline NASH 5-8: NASH Kleiner, Hepatology 2005 Pathology Committee of NASH, Clinical Research Network-CRN, NIH NASH CRN)

Staging fibrosis in NAFLD THV PT PT THV THV MacSween s Pathology of the Liver 2012

Scoring activity and staging fibrosis in NAFLD NASH CRN thresholds do not always correlate with histological diagnosis NASH CRN system has not been validated in routine Used only for research purposes in clinical trials

Algorithm for disease classification in NAFLD Bedossa et al, Hepatology 50; 1751-9, 2012 Ballooning Lobular Inflammation Steatosis

Scoring NAFLD in morbidly obese patients Bedossa et al, Hepatology 2012 Simple algorithm for categorizing liver injury in NAFLD Exclusion of steatosis (0-3) from grading of disease activity lobular Activity grade (0-4): sum of ballooning (0-2) and inflammation (0-2) 0 1 1 2 2

Scoring NAFLD in morbidly obese patients Bedossa et al, Hepatology 2012 Simple algorithm for categorizing liver injury in NAFLD Exclusion of steatosis (0-3) from grading of disease activity lobular Activity grade (0-4): sum of ballooning (0-2) and inflammation (0-2) Fibrosis stage: as in NASH-CRN SAF score: Steatosis (0-3), Activity (0-4), Fibrosis (0-4) S 3 A 2(1+1) F 1 S 1 A 4(2+2) F 4

6 expert liver pathologists 10 general pathologists

Interobserver agreement using SAF score Steatosis κ = 0.61 Substantial Activity Ballooning Lobular Inflam. Fibrosis (1a,b,c-2-3-4) Fibrosis (1-2-3-4) κ = 0.75 κ = 0.8 κ = 0.72 κ = 0.53. κ = 0.83 Substantial Moderate Perfect SAF score : highly reproducible semiquantitative features

Scoring activity in Alcoholic Liver Disease In ALD the use of grading systems is very limited 2014: Semiquantitative histological score with prognostic value - Alcoholic Hepatitis Histological Score (AHHS 0-7) lobular infiltration by polymorphs bilirubinostasis megamitochondria stage of fibrosis Altamirano, Gastroenterology 2014; 146: 1231 90-day survival

Medizinische Fakultät Institut für Pathologie 2014 What s hot Chronic liver disease Fibrosis Cirrhosis DILI Fatty liver disease Biliary disease Benign tumours Malignant tumours

Staging and Grading Primary Biliary Cirrhosis

Staging and Grading Primary Biliary Cirrhosis

Staging and Grading Primary Biliary Cirrhosis

Rates of development of cirrhosis-related conditions New Japanese system system Ludwig system Scheuer system The new system correlates with clinical and pathological features reflects liver dysfunction n=152

Japanese staging correlated with progression-free survival in PBC n=58, follow-up 16.9 years Chan, Histopathology 2014; 65:174-186 Copper-associated protein deposition score: most powerful histologic prognostic parameter

Liver Int 2014 June 17 Fibrosis (0-4) Bile duct ratio (n PT with BD/n PT) Interface hepatitis, lymphocytic (0-3)

Liver Int 2014 June 17 Fibrosis (0-4) Bile duct ratio (n PT with BD/n PT) Interface hepatitis, lymphocytic (0-3)

Wahl, Hepatology Sept 10, 2014

Medizinische Fakultät Institut für Pathologie 2014 What s hot Chronic liver disease Benign liver tumours Malignant tumours

D.D. of FNH and I-HCA Modern Pathol 2014; 27:62-72 FNH Glutamine synthetase (GS) Comparison of pattern and extent of immunoreactivity within the tumour to that in the adjacent liver Saxena, Practical Hepatic Pathology 2013

D.D. of FNH and I-HCA Modern Pathol 2014; 27:62-72 I-HCA Glutamine synthetase (GS)

IHC of FNH and HCA GS GS SAA SAA 17.5% of FNH show SAA positivity 15% of I-HCA show FNH-like GS pattern (map-like)

FNH

HCA

Medizinische Fakultät Institut für Pathologie 2014 What s hot Chronic liver disease Benign liver tumours Malignant liver and biliary tract tumours HCC Intrahepatic cholangiocarcinoma

IHC markers for diagnosing HCC Most frequently used: HepPar1 arginase 1 polyclonal CEA CD10 Hepatocellular differentiation Canalicular markers Yan, Am J Surg Pathol 2010 Glypican-3 (GPC-3) - marks HCC, but generally not benign hepatocytes - therapeutic target in HCC Filmus & Capurro, FEBS J 2013

Bile Salt Export Pump as a marker of HCC Lagana, Histopathology 2014 Nov 6, in press

Bile Salt Export Pump as a marker of HCC Lagana, Histopathology 2014 Nov 6, in press BSEP is a highly sensitive and specific marker for HCC No need to identify a canalicular pattern!

HCC expressing stemness -related markers HCC that express stemness -related markers (keratin 19, EpCAM, CD133, CD117) show more aggressive behaviour and have poor prognosis EpCAM K19 Durnez, Histopathology 2006 Yamashita, Cancer Res 2008 Theise, WHO 2010 Kim, Hepatology 2013 Chan, Histopathology 2014

IHC 241 HCC, molecular profiling (mrna, microrna), in vitro assays Keratin 19 expression in HCC confers an invasive phenotype

IHC 241 HCC, molecular profiling (mrna, microrna), in vitro assays Keratin 19 expression in HCC confers an invasive phenotype by intersecting with pathways involved in cytoskeleton dynamics and cell motility is associated with chemoresistance K19-positive HCC should be diagnosed and treated as a separate entity of HCCs (?)

HCC expressing stemness -related markers SALL4, an oncofetal antigen, is a new marker of HCC with progenitor-like gene signatures

SALL4 expression in HCC SALL4 is absent from normal liver Yong KJ, NEJM 2013

SALL4 expression in HCC Overexpression of proliferation- and metastasis-related genes in SALL4 (+) HCC SALL4 immunopositivity is a marker of poor prognosis in HCC Yong KJ, NEJM 2013

SALL4 expression in HCC The absence of SALL4 expression from healthy adult liver enhances the potential of SALL4 as a treatment target in HCC Inhibition of tumour formation by specific targeting of SALL4 in xenograft models Yong, NEJM 2013 Zeng SS, J Hepatol 2014

1.3% SALL4+ (3/236 HCC) correlation with high grade Am J Surg Pathol 2014; 38:966-72

A new approach to histopathological classification of primary liver carcinoma Roncalli, Dig Liv Dis 2010

Medizinische Fakultät Institut für Pathologie 2014 What s hot Chronic liver disease Benign liver tumours Malignant liver tumours HCC Cholangiocarcinoma

Cell origins of Cholangiocarcinoma Razumilava & Gores

Targetable cholangiocarcinoma signalling pathways

Int J Hepatol 2014, ID 805973

Hilar cholangiocarcinoma

Hilar cholangiocarcinoma vs PDAC Hilar CC PDAC Alcian blue AGR2 S100P NCAM ICC chc-ccc PDAC Hilar CC Gandou, Hum Pathol 2013

Summary (1) Histological sub-classification of cirrhosis becomes a reality Digital evaluation of fibrosis by image analysis is superior to histology for comparisons with HVPG, evaluation of prognosis and correlations with noninvasive fibrosis methods qfibrosis is superior digital method for assessing fibrosis compared to the better known CPA Tissue angiogenesis is proposed to be included in histological assessment of CLD 2014 What s hot

Summary (2) DILI: - limited correlation between biochemical and pathological injury patterns - Severe or fatal injury is associated with necrosis, microvesicular steatosis, ductular reaction and fibrosis stage Perilipin, a lipid droplet associated protein, may be used for the differential diagnosis between chronic and acute steatosis 2014 What s hot

Summary (3) A new histological scoring system (SAF) and a classifier algorithm for NAFLD has been validated and helps decrease interobserver variability for NASH diagnosis Histological scoring systems with prognostic value have recently been developed for alcoholic hepatitis New histological staging and grading systems for PBC appear superior to classical staging systems FBI is simpler and has higher inter-observer agreement compared to the Japanese system 2014 What s hot

Summary (4) BSEP is a highly sensitive and specific new marker for HCC HCC that express stemness -related markers show more aggressive behaviour and poor prognosis Re-classification of primary liver carcinomas is the focus of intense research: a spectrum with carcinomas showing HC differentiation in one end and CC in the other 2014 What s hot

Summary (5) Different cell origin underlies the histological diversity of intrahepatic cholangiocarcinomas Precursor lesions of distal (peripheral) intrahepatic cholangiocarcinomas have been proposed The similarities between hilar cholangiocarcinomas and PDAC may reflect common pathogenesis based on embryology 2014 What s hot

Ding, Hepatology 2014; 59:1235-7